

# Becker Muscular Dystrophy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/BC86CA48990EN.html>

Date: February 2020

Pages: 75

Price: US\$ 2,000.00 (Single User License)

ID: BC86CA48990EN

## Abstracts

Becker Muscular Dystrophy - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2020, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 4 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Becker Muscular Dystrophy - Overview
- Becker Muscular Dystrophy - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Becker Muscular Dystrophy - Therapeutics Assessment
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
  - Armgo Pharma Inc
  - Catabasis Pharmaceuticals Inc
  - Edgewise Therapeutics
  - Epirium Bio Inc
  - Italfarmaco SpA
  - Milo Biotechnology LLC
  - PTC Therapeutics Inc
  - ReveraGen BioPharma Inc
  - Sarcomed AB
  - Tivorsan Pharmaceuticals Inc
- Becker Muscular Dystrophy - Drug Profiles
  - ARM-210 - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - ataluren - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - edasalonexent - Drug Profile
    - Product Description
    - Mechanism Of Action
    - R&D Progress
  - EDG-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epicatechin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker

Muscular Dystrophy And Inclusion Body Myositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nandrolone decanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vamorolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Becker Muscular Dystrophy - Dormant Projects

Becker Muscular Dystrophy - Discontinued Products

Becker Muscular Dystrophy - Product Development Milestones

Featured News & Press Releases

Feb 10, 2016: Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy

Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference

Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference

Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound

May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound

Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Becker Muscular Dystrophy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Becker Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H1 2020  
Becker Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2020  
Becker Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H1 2020  
Becker Muscular Dystrophy - Pipeline by Epirium Bio Inc, H1 2020  
Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2020  
Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2020  
Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2020  
Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2020  
Becker Muscular Dystrophy - Pipeline by Sarcomed AB, H1 2020  
Becker Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, H1 2020  
Becker Muscular Dystrophy - Dormant Projects, H1 2020  
Becker Muscular Dystrophy - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Becker Muscular Dystrophy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Armgo Pharma Inc

Catabasis Pharmaceuticals Inc

Edgewise Therapeutics

Epirium Bio Inc

Italfarmaco SpA

Milo Biotechnology LLC

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Sarcomed AB

Tivorsan Pharmaceuticals Inc



## I would like to order

Product name: Becker Muscular Dystrophy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/BC86CA48990EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC86CA48990EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970